Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

LCAOS

Financiado

Cerrado

A Nanoscale Artificial Nose to easily detect Volatile Biomarkers at Early stages...

A Nanoscale Artificial Nose to easily detect Volatile Biomarkers at Early stages of Lung Cancer and Related Genetic Mutations The LCAOS project will develop and test a new diagnostic tool, able to detect: (i) the presence of lung cancer (LC), and (ii) an increased risk of a patient developing LC in the future. Diagnostic tests currently available are uns... ver más

31/03/2015

TECHNION ISRAEL I...

5M€

Presupuesto del proyecto: 5M€

Líder del proyecto

TECHNION ISRAEL INSTITUTE OF TECHNOLOGY No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 9 Participantes

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2015-03-31 No tenemos la información de la convocatoria

0% 77% 100%

Características del participante

Este proyecto no cuenta con búsquedas de partenariado abiertas en este momento.

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

9 Participantes

TECHNION ISRAEL INSTITUTE O...

0.00€ | Lider

MPG

N.D. | Participante

IONICON ANALYTIK GMBH

N.D. | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Líder del proyecto

TECHNION ISRAEL INSTITUTE OF TECHNOLOGY No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 5M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto The LCAOS project will develop and test a new diagnostic tool, able to detect: (i) the presence of lung cancer (LC), and (ii) an increased risk of a patient developing LC in the future. Diagnostic tests currently available are unsuitable for widespread screening because they are costly, occasionally miss tumours, are not time-efficient, nor free of complications. LCAOS will overcome these problems by using an approach based on volatile biomarkers emitted from cell membranes. A multidisciplinary effort, incorporating nanotechnology, biomedical engineering, medical oncology, and computation strategies, will develop a highly-sensitive, inexpensive, and fast-response, non-invasive, artificial nose (known as, NaNose), building on the coordinator’s earlier success in this area. The NaNose will be able to detect pre-neoplastic volatile biomarkers that indicate an increased genetic risk of LC, and the presence of LC. It has already been established that these biomarkers can be detected either directly from the headspace of the cancer cells or via exhaled breath. LCAOS will: (i) develop arrays of chemically-sensitive field effect transistors (FETs) of non-oxidized, molecule-terminated silicon nanowires (Si NWs); (ii) test the ability of these devices to sense volatile LC biomarkers from in-vitro tissue, and exhaled human breath; (iii) study the signal transduction mechanism of the volatile biomarkers, using pattern recognition; (iv) improve systems to enable the NaNose to distinguish the targeted biomarkers from environmental clutter, using methylation, expression profiling, and genome-wide sequencing; and (v) perform clinical-related studies to assess LC conditions in actual patients & tissues, and in the presence of real-world confounding signals. Validation will be carried out by clinician partners and professional mathematicians and computer scientists. Resources will also be allocated to ensure the commercial potential of the sensor device layout.

Conecta tu I+D

Entra hoy

Forgot your password?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores